iiinova — where your digital self keeps evolving

David van Duin @davidvanduin.bsky.social · 23/06/2026

Kidney and liver recipients with about half and more than half seropositivity #ATC2026 2/n

100

David van Duin @davidvanduin.bsky.social · 23/06/2026

Dr. Durand presents on Kaposi Sarcoma herpesvirus in SOT recipients with HIV. 1/n #ATC2026

100

David van Duin @davidvanduin.bsky.social · 23/06/2026

Dr. Shams now presents on BKV in polycystic kidney disease kidney transplant recipients. 342 adpkd recipients matched to 1026 controls BKV viremia 27% in both groups. BKV nephropathy 6% in both groups No impact of adpdk on bk risk. 1/2 #ATC2026

100

David van Duin @davidvanduin.bsky.social · 23/06/2026

Dr. Lentine now presents on APOL1 genotype related outcomes in living donor kidney transplantation. APOL1 in donors associated with poor renal function in recipient jamanetwork.com/journals/jam... #ATC2026

010

David van Duin @davidvanduin.bsky.social · 23/06/2026

These are most encouraging results in an area where no therapy options besides lowering IS are currently available #ATC2026 4/4

000

David van Duin @davidvanduin.bsky.social · 23/06/2026

Results encouraging with higher proportion of mab-treated patients reaching BKV VL reduction 3/n

100

David van Duin @davidvanduin.bsky.social · 23/06/2026

42 patients on drug and 42 on placebo 36 days of BKV viremia. Prior to treatment, 21% in mab arm already diagnosed with BK nephropathy vs 10% in placebo arm #ATC2026 2/n

100

David van Duin @davidvanduin.bsky.social · 23/06/2026

#ATC2026 At plenary session, Dr. Dadhania present results of anti-BK monoclonal mab potravilug which binds VP1 epitopes of the virus. Phase 2 study placebo controlled. 1/n

100

David van Duin @davidvanduin.bsky.social · 27/05/2026

Talented transplant ID fellow at UNC Dr Swarn Arya presents this morning on prophylaxis against C. difficile in HSCT recipients. academic.oup.com/cid/article/...

020

David van Duin @davidvanduin.bsky.social · 23/05/2026

@trtalbot.bsky.social gave great talk on infection prevention at ESGARS meeting in Athens, emphasizing building relationships and long term investments (and data!) @escmid.bsky.social

230

David van Duin @davidvanduin.bsky.social · 22/05/2026

Can’t beat Athens! Grateful to ESGARS study group of @escmid.bsky.social

010

David van Duin @davidvanduin.bsky.social · 22/05/2026

Dr. Onder Ergonul now presents on hypervirulent carbapenem-resistant K. pneumoniae in turkey www.tandfonline.com/doi/10.1080/... @escmid.bsky.social @angelahuttner.bsky.social

220

David van Duin @davidvanduin.bsky.social · 22/05/2026

Dr Laurent Poirel now up talking about new treatment options for carbapenem resistant A. baumannii. ATTACK trial crucial in this field showing role for sulbactam-durlobactam (note combined with imipenem in all patients in this trial) www.thelancet.com/journals/lan... @esgarsociety.bsky.social

110

David van Duin @davidvanduin.bsky.social · 22/05/2026

Dr. Paul Higgins now discussing carbapenem-resistant A. baumannii. Hyper-regional epidemiology related to prolonged hospital associated outbreaks. OXA carbapenemases most common cause of carbapenem resistance. nice ARLG-sponsored work: academic.oup.com/cid/article/... @esgarsociety.bsky.social

120

David van Duin @davidvanduin.bsky.social · 22/05/2026

Dr. Sophie Baron from Marseille now presents on high-risk Enterobacterales clones. An example here for K. pneumoniae journals.asm.org/doi/10.1128/... @esgarsociety.bsky.social @escmid.bsky.social

110

David van Duin @davidvanduin.bsky.social · 22/05/2026

@souhakanj.bsky.social shares the challenges to infection prevention and antimicrobial stewardship in setting of conflict and war. A picture from american university of beirut medical center. @esgarsociety.bsky.social

110

David van Duin @davidvanduin.bsky.social · 22/05/2026

@souhakanj.bsky.social now up (virtually unfortunately 😕) to talk about antimicrobial stewardship in LMIC @esgarsociety.bsky.social

110

David van Duin @davidvanduin.bsky.social · 22/05/2026

Dr. Carattoli: resistance plasmids characterized by incredible complexity combining carriage of resistance and virulence genes. @esgarsociety.bsky.social

120

David van Duin @davidvanduin.bsky.social · 22/05/2026

Dr. Alessandra Caratolli now discusses resistance plasmids in Gram-negative bacteria. Starts with IncL-OXA-48 A recent paper describing this plasmid in @jac-amr.bsky.social here: academic.oup.com/jacamr/artic... @esgarsociety.bsky.social

111

David van Duin @davidvanduin.bsky.social · 21/05/2026

Dr. Goettig: remember to clean your phone when working in healthcare settings @esgarsociety.bsky.social @escmid.bsky.social @taescmid.bsky.social

020

David van Duin @davidvanduin.bsky.social · 21/05/2026

Dr. Naas: lateral flow looking for carbapenemases can be directly performed from positive blood cultures Published in @jac-amr.bsky.social @esgarsociety.bsky.social

010

David van Duin @davidvanduin.bsky.social · 21/05/2026

Lateral flow assays work well to detect main types of carbapenemases. Rapid and affordable without requiring a cold chain. @esgarsociety.bsky.social

000

David van Duin @davidvanduin.bsky.social · 21/05/2026

Dr. Thierry Naas now presents on novel ID diagnostics in carbapemase detection. AI-guided interpretation may be helpful to predict carbapenemases. @esgarsociety.bsky.social @escmid.bsky.social

000

David van Duin @davidvanduin.bsky.social · 21/05/2026

Dr Karakosta now presents on outcomes of patients screen positive for carriage of CRO, VRE and/or C. Diff in Greece. High carriage rates 20% CRO (k. Pneumo, crab, psa) 35% VRE 10% c. Diff RF as expected (healthcare + abx) unadjusted OR of 9 for subsequent CRE BSI @esgarsociety.bsky.social

000

David van Duin @davidvanduin.bsky.social · 21/05/2026

Very high carbapenem resistance rates (>85%!) in K. pneumoniae from nosocomial BSI with a rise in NDM between 2020-2025 in a Greek hospital. Presented at ESGARS meeting in Athens @escmid.bsky.social @esgarsociety.bsky.social

000

David van Duin @davidvanduin.bsky.social · 14/05/2026

Dr. Elda Righi (Associate Editor for @jac-amr.bsky.social) now chairing the last session of the day. Invited papers supported by JAC and JAC-AMR @bsacandjac.bsky.social Should be great session covering patient perspectives, the UK antibiotic registry, big data, and more

020

David van Duin @davidvanduin.bsky.social · 14/05/2026

Dr. Denning now presents on global burden of fungal disease: Epidemiology, trends & emerging threats. Talking about azole resistance in Aspergillus. Very geographically variable and linked to non-clinical antifungal use eg agriculture. For recent review global epi: academic.oup.com/jacamr/artic...

210

David van Duin @davidvanduin.bsky.social · 14/05/2026

Dr. Donnelly of JAC fame describes common perception of reviewers in medical publishing. @bsacandjac.bsky.social #IDsky

074

David van Duin @davidvanduin.bsky.social · 14/05/2026

Dr Peter Donnelly now giving the Garrod lecture. Such an impressive career @bsacandjac.bsky.social

100

David van Duin @davidvanduin.bsky.social · 14/05/2026

Laura Ahearn, RN now speaking on the essential role of RN in antimicrobial stewardship. @bsacandjac.bsky.social Important message that without appropriate diagnosis, good stewardship is impossible

120

David van Duin @davidvanduin.bsky.social · 14/05/2026

Dr. Cooper: pilot project on delinkage with caz-avi and cefiderocol. Value in QALYs higher for cefiderocol (16,200) vs caz-avi (8,880) in a model of 20 years. Details on www.nice.org.uk @bsacandjac.bsky.social

030

David van Duin @davidvanduin.bsky.social · 14/05/2026

Dr. Sophie Cooper from the UK National Institute of Health and Care Excellence (NICE). Speaking on de-linkage for antibiotics. In UK subscription model: pay for antibiotics regardless of volume used, based on perceived society benefits (Prof Rex: abx as fire extinguishers of medicine)

110

David van Duin @davidvanduin.bsky.social · 14/05/2026

President Andrew Seaton opens the spring conference for BSAC. >10,000 members currently #IDsky bsac.org.uk/membership/

120

David van Duin @davidvanduin.bsky.social · 08/05/2026

Great to have Dr Jay Fishman from Harvard coming to talk to us about transplant ID at UNC

000

David van Duin @davidvanduin.bsky.social · 21/04/2026

Next up: Dr Lauren Saint from UNC discusses a case of joint swelling in knee, finger, toe. Skin lesions and painful eye with blurry vision and increased eye pressure and uveitis leading to loss of vision in eye. US travel only. Transports live pigs as truck driver.

131

David van Duin @davidvanduin.bsky.social · 21/04/2026

Very wide differential offered by experts. Schistosomiasis was first thing mentioned by David Paterson! discussing CNS TB; CSF PCR was negative but not sufficient. 3 further schistosomiasis tests positive Treatment: ivermectin (for strongy), praziquantel, Dex Patient improved #ESCMIDGlobal2026

000

David van Duin @davidvanduin.bsky.social · 19/04/2026

Dr. Kontoyiannis: 58% of leukemia treatments in development have interactions with azole antifungals and of course many currently approved agents have similar concerns. This is already resulting in many patients on second line prophylaxis #ESCMIDGlobal2026

010

David van Duin @davidvanduin.bsky.social · 19/04/2026

Now emphasizing the importance of breakthrough fungal infections in patients on azole prophylaxis which are associated with worse outcomes #ESCMIDGlobal2026

110

David van Duin @davidvanduin.bsky.social · 19/04/2026

Dr Kontoyiannis now giving key note in ICM14 Starts with fascinating history of IFI in leukemia #ESCMIDGlobal2026

121

David van Duin @davidvanduin.bsky.social · 18/04/2026

Now up: a change of pace looking at how new antibacterials should be evaluated. Conducting stand-alone two-arm trials very time and money consuming. Dr. Melissa Hardy proposes GNR research should take a page out of SNAP playbook and conduct platform trials instead. #ESCMIDGlobal2026

241

David van Duin @davidvanduin.bsky.social · 18/04/2026

Next: anti-Psa antibody in patients with bronchiectasis (GREAT-2) Gremubamab was given every four weeks in two different doses. Psa bacterial loads reduced for both doses Higher dose delayed time to first exacerbation Sequencing & binding assays: no resistance development #ESCMIDGlobal2026

261

David van Duin @davidvanduin.bsky.social · 18/04/2026

Now up: tebipenem Subgroup analysis of pivot-po their cUTI study (~50% MDR) Overall pivot-po: tebipenem non-inferior to imipenem. Importantly tebipenem folks received IV placebo so no benefit of avoiding infusions measured In BSI and SIRS positive numerically favored imipenem #ESCMIDGlobal2026

021

David van Duin @davidvanduin.bsky.social · 18/04/2026

In integral-2 nacubactam (+FEP OR ATM) compared to BAT for CRE infections Small study but results encouraging #ESCMIDGlobal2026

031

David van Duin @davidvanduin.bsky.social · 18/04/2026

Packed room (ICM13b) for novel antibiotics Nacubactam up first Exciting stand-alone approach for this bli-enhancer Combined with aztreonam or cefepime #ESCMIDGlobal2026

210

David van Duin @davidvanduin.bsky.social · 18/04/2026

Dr Maaike van Mourik (UMC) now up: - on-demand WGS vs routine WGS: large scale WGS - unsurprisingly- identifies many previously unrecognized transmission events www.clinicalmicrobiologyandinfection.org/article/S119...

100

David van Duin @davidvanduin.bsky.social · 18/04/2026

#ESCMIDGlobal2026 Nico Mutters kicks off the year in IP So far: - fake nails not that bad - people still don’t know how to wash their hands - PPE: long-sleeved gowns unclear helpful for respiratory virus, and unsurprisingly results in lots of waste (Singapore Hospital 66,000kg plastic waste)

261

David van Duin @davidvanduin.bsky.social · 31/10/2025

Looking forward to UNC Institute of Global Health and Infectious Diseases Friday talk globalhealth.unc.edu/education/fr...

131

David van Duin @davidvanduin.bsky.social · 21/10/2025

Dr Cesar Arias delivers Maxwell Finland Lecture #IDweek2025 “Antimicrobials save the patient and reduce infectiousness” “My research comes from a question in one patient” 💯

071